Resources

WoundSkin® FactsheetHuman ex vivo skin model to study wound healing & bacterial infectionWoundSkin® Factsheet: Advance Your Wound Healing Research Download the WoundSkin® factsheet to explore how a physiologically relevant, wounded human skin model can support your wound healing and infection research. Built on ex vivo human skin tissue, WoundSkin® preserves the full complexity of native skin, including immune responses, whileRead more

Genoskin appoints new board memberto strengthen governancePress releaseGenoskin Strengthens Governance with Appointment of Industry Leader Fabrice BouteilleA strategic milestone reinforcing independence, global growth, and leadership in human-relevant researchA new chapter in Genoskin’s growth journey Genoskin announces the appointment of Fabrice Bouteille as an independent member of its Board of Directors—marking a pivotal step in the company’s evolution following its $8.7Read more

Intradermal device testingA collaboration study with Pharma LatchReplacing animal testing in local tolerance assessment of an injection device: Human ex vivo HypoSkin® model as a New Approach Methodology (NAM) Jérémy Argenty1, Clémence Letzelter1, Catherine Marques1, Sophie Abadie1, Alexia Sanchez1, Claire Gendrin1, Alexandra Ochando1, Adam Rock2, Ronan Byrne2, Pascal Descargues1, Nicky Bertollo2 1Genoskin, 2Pharma Latch HypoSkin® is an ex vivo human skin NAM thatRead more

Local toxicity & Formulation safetyA collaboration study with argenxHypoSkin® as a human-based NAMs platform for local toxicity and formulation safety assessment Julie Magerman1, Katarzyna Polak2, Ornella Binazon1, Michael Pastore2, Alexandra Ochando2, Judith Baumeister1 1argenx, 2Genoskin Formulation safety testing still relies heavily on in vivo studies due to limited validated in vitro alternatives. Genoskin’s HypoSkin® biostabilized ex vivo human skin enables multi-parametric local tolerance assessment after subcutaneous injection.Read more

Genoskin & argenx showcasehuman-based NAM platformPress releaseGenoskin presents translational human-based NAM platform at SOT 2026 in collaboration with argenxAdvancing New Approach Methodologies (NAMs) with human skin modelsAt the 2026 annual meeting of the Society Of Toxicology (SOT), we will present new data demonstrating the value of our HypoSkin® ex vivo human skin platform as a translational human-based New Approach MethodologyRead more

Top-level science through the eyes of an expert.Preclinical evaluation of an energy-driven device for localized skin delivery of nucleic acidsDid you miss the live session? The full webinar recording is now available to watch on demand. Explore preclinical insights into an energy-driven, microneedle-based device enabling localized, non-viral delivery of naked nucleic acids to skin, highlighting transgene expression, immune activation, andRead more